Consumers urged to file claims from $96.5 million generic drug price-fixing settlements
A federal court has given preliminary approval to a plan by Connecticut and 47 other states and territories to distribute settlement money from six generic drug makers accused of conspiring to inflate prices. People who bought certain generic drugs between 2009 and 2019 may be eligible.
People who bought certain generic drugs over the past decade may be able to claim money from a set of price-fixing settlements totaling about $96.5 million, Connecticut Attorney General William Tong said Tuesday.
The U.S. District Court for the District of Connecticut has granted preliminary approval to a plan, filed by Connecticut and 47 other states and territories, to distribute money paid by generic drug manufacturers to settle claims that they illegally conspired to raise prices, Tong's office said.
The settling companies are Glenmark, Lannett, Bausch, Apotex, Heritage and Heritage's parent company, Emcure, according to the attorney general's office. People who bought one of the generic drugs covered by the settlements between May 2009 and December 2019 may be eligible for payment. Eligibility can be checked at www.AGGenericDrugs.com.
Connecticut is leading a coalition of nearly all states and territories in a series of antitrust cases that began in 2016, prosecutors said. A second case was filed in 2019 against Teva Pharmaceuticals and 21 other manufacturers, and a third, covering 80 topical generic drugs, is set to be tried first. A fourth complaint targets Novartis AG, Sandoz Group AG and Sandoz AG.
The allegations in the cases that have not settled have not been tested at trial.
"Major players across the generic drug industry rigged the market and forced customers to pay higher prices for critical medication," Tong said.
This brief was drafted by AI from a public agency press release and published by The New England Signal. Why we use AI for stories like this one.